Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. - Wikidata - awgldk - TriplyDB

Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

http://www.wikidata.org/entity/Q53964449

about

betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player?Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho)Mucin-type O-glycosylation during development Regulation and function of the FGF23/klotho endocrine pathways Exploring mechanisms of FGF signalling through the lens of structural biology A potential link between phosphate and aging--lessons from Klotho-deficient mice The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice Regulation of fibroblast growth factor-23 signaling by klotho Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts.The use of fibroblast growth factor 23 testing in patients with kidney disease.Urinary prostaglandins and the effect of indomethacin on phosphate excretion in children with hypophosphatemic rickets.Phosphate-induced apoptosis of hypertrophic chondrocytes is associated with a decrease in mitochondrial membrane potential and is dependent upon Erk1/2 phosphorylation.Fibroblast growth factor-23 increases mouse PGE2 production in vivo and in vitro.Mineral metabolism and aging: the fibroblast growth factor 23 enigma.FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.Phosphatonin washout in Hyp mice proximal tubules: evidence for posttranscriptional regulation.Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis.Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.The changing face of hypophosphatemic disorders in the FGF-23 era FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease.Recent advances in renal phosphate handling.Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the liver-transplant waiting list.FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues.The roles of the skeleton and phosphorus in the CKD mineral bone disorder Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease.Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease.Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.FGF-23: More than a regulator of renal phosphate handling?

P2860

Q24306279-FAE044AD-7E3F-4DCC-9539-519CACBD8116 Q24319643-AC62B15F-CEE8-4C7E-A8BF-8D749422ADBC Q24530025-08DF6A34-6394-4DFB-B497-1DDF2D8B41ED Q24653541-900ED696-FEB5-4E29-8D3B-35861ADBD06A Q24683254-4ABADF0E-80D6-4641-BC55-CEE9F2FE5453 Q26827280-15CAFA33-E857-40AF-8DEB-E8F24A77A2F7 Q26849608-9CDD14BB-B623-4C03-A690-9547B15CDEE2 Q26860470-B4BDE236-195F-4B01-B843-F25E230E4F50 Q27015054-F20F7763-31D0-495E-AC35-372F969E2D23 Q27687316-2563BA10-29E1-405B-AEC9-EF798C2E37CB Q28202356-1C4E6485-B57A-4549-99E4-71BBA340FDE8 Q28213962-429F6F85-A9BE-4D18-82D6-1BEC7E97FB83 Q28291993-8748A759-A08F-4C54-AB72-CA9FCE236B76 Q28485340-4CA89548-6769-426B-8C87-57C2B50E94CD Q28507303-238BB693-BFD3-48B8-8473-198814C3D3D2 Q28587100-A10E4166-AD74-4558-AD12-532DB792EEE3 Q29620323-B0821E78-5D5B-43F6-87AE-A442BC7FEB82 Q33591785-062F270C-D2C9-4B8E-A973-6FFB7467450C Q33736093-980E1E1E-EBD4-4BED-AD56-E8244927BDCB Q33793927-B1BE926E-D360-4B06-93A2-528F1113AD0A Q33835743-51733F36-2888-4DB3-AD98-46DBD9566738 Q33897553-AEF64FCD-AC37-4224-A2F4-8D79D0029919 Q33897727-421AD403-AE37-45BE-9856-445020693017 Q33897866-60CCDD36-1B4B-42C0-BAF8-3CD411573F86 Q33982618-50A20D6F-7CEE-46BA-9372-DABD3AF9E4E2 Q34017992-DF3242F9-EA2C-420D-BBA2-F475E9CC653D Q34030128-5D0E79D7-58B9-4761-A351-9DD7BD2D7D89 Q34069793-0EF75396-E2BF-4F2D-8043-B83EF4EC2D13 Q34185739-3DA2C1F6-52F9-4461-A992-9678686D5F5B Q34221238-7FCD0713-E180-4D5F-8811-63A46250C30A Q34227442-10252B6F-17C2-4AF1-AE51-F42674B9DDE4 Q34253710-A60B90C6-A535-4CD7-AFFF-AE0A51764152 Q34631794-F130D30A-3D61-4DD9-BADB-9EE04E726190 Q34794004-93AC7E6E-E67E-4439-B318-7706B6BCCA11 Q34982729-04D1E736-52AD-4231-A05D-30569C335124 Q35013304-7277C72F-A89C-4F78-AF93-B02F260867CB Q35067500-F60DF1B6-1C10-482D-BF4F-0191C272A2ED Q35075064-1DA8BB4A-B706-48CF-82B5-4C495E55639C Q35151453-CEAB4535-735D-4685-9427-2D62C12AF25D Q35156017-42E8E00F-C770-4A7E-ADED-40173A9AF681

P2860

Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

http://www.wikidata.org/entity/Q53964449

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Mutant FGF-23 responsible for ...... uses hypophosphatemia in vivo.

@en

Mutant FGF-23 responsible for ...... uses hypophosphatemia in vivo.

@nl

type

label

Mutant FGF-23 responsible for ...... uses hypophosphatemia in vivo.

@en

Mutant FGF-23 responsible for ...... uses hypophosphatemia in vivo.

@nl

prefLabel

Mutant FGF-23 responsible for ...... uses hypophosphatemia in vivo.

@en

Mutant FGF-23 responsible for ...... uses hypophosphatemia in vivo.

@nl

P1433

Q53964449-EA1CDC53-E4AD-433A-81AF-B2F0B5A21E76

P1476

Q53964449-8938E7A5-1C7D-4D72-B848-BF1C35581054

P2093

Q53964449-0468CB9A-54C5-4E8C-9DB7-C81CD198D0BD

Q53964449-14D7B150-F464-4933-AF8A-74564DC2F7A4

Q53964449-1EE9D924-9BA8-4236-983B-E045AC4B7B45

Q53964449-212FAA4C-CFBB-483F-8EA0-027EBDF15282

Q53964449-591F815B-50AF-4C29-A3A3-C0DFB21EA993

Q53964449-6316D94B-1A6A-407D-A577-5F38313B8C42

Q53964449-77511607-3B6D-4E16-933A-15E6E83F408A

Q53964449-77C0092F-171C-4185-A6B4-852DD03E0D46

Q53964449-B46FA03B-7DB2-4434-A80D-9D18F4FCAF16

Q53964449-C85E870E-5928-4966-832F-AC537F695512

P304

Q53964449-3EAFEF24-A55D-4C4A-8E32-0FC2751A87A8

P31

Q53964449-3C9B40B8-CE2C-4B9E-9448-1FBAB3EE2A9F

P356

Q53964449-3587D2FD-C950-4149-A035-A2966B8D2BA5

P407

Q53964449-510D1547-DA14-40CB-BCEF-55A125A13384

P433

Q53964449-EAB41C1E-59C4-458F-B08E-F8C170159AE0

P478

Q53964449-8F87CE7F-1331-4D09-8EB4-6B0BCFA0373A

P577

Q53964449-CE8B6D9A-808F-42B7-8A54-0AFE305C46DF

P5875

Q53964449-FDEEB287-5ED1-4572-B209-B921D7B96651

P698

Q53964449-F53D7392-E22A-4676-8FEC-8300EA175F78

P921

Q53964449-02EBF952-2165-4364-B9FD-6F22A6F8C5FB

Q53964449-E7D62684-CC2F-4D80-AED8-155241CAFC11

P356

P1433

P1476

Mutant FGF-23 responsible for ...... uses hypophosphatemia in vivo.

@en

P2093

Itaru Urakawa

http://www.w3.org/2001/XMLSchema#string

Katsuya Okawa

http://www.w3.org/2001/XMLSchema#string

Seiji Fukumoto

http://www.w3.org/2001/XMLSchema#string

Takanori Muto

http://www.w3.org/2001/XMLSchema#string

Takashi Shimada

http://www.w3.org/2001/XMLSchema#string

Takashi Yoneya

http://www.w3.org/2001/XMLSchema#string

Takeyoshi Yamashita

http://www.w3.org/2001/XMLSchema#string

Toshiro Fujita

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Takeuchi

http://www.w3.org/2001/XMLSchema#string

Yuji Yamazaki

http://www.w3.org/2001/XMLSchema#string

P304

3179-3182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/EN.143.8.3179

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

143

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11250273

http://www.w3.org/2001/XMLSchema#string

P698

12130585

http://www.w3.org/2001/XMLSchema#string

P921

autosomal dominant hypophosphatemic rickets